

## SUPPLEMENTARY MATERIAL

### Sizing up the Next Generation of Nanomedicines

Jeffrey D. Clogston <sup>1</sup>‡, Vincent A. Hackley <sup>2</sup>, Adriele Prina-Mello <sup>3</sup>, Sanyogitta Puri <sup>4</sup>, Silvia Sonzini <sup>4</sup>, Patrick Lim Soo <sup>5</sup>‡

<sup>1</sup> Nanotechnology Characterization Laboratory (NCL), Leidos Biomedical Research, Inc., Frederick, MD, USA

<sup>2</sup> National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA

<sup>3</sup> Trinity College Dublin, Dublin, IR

<sup>4</sup> AstraZeneca UK LTD, Cambridge, UK

<sup>5</sup> Pfizer Inc., Novel Delivery Technologies- PhRD, 68 Lowell Junction Road, Andover, MA, USA

‡ Corresponding authors

#### Criteria and resources used to determine the number of nanoparticle formulations approved in the US and EU.

PharmaCircle research in Drug Delivery Technology Analyzer. Keywords used: DD technology: Nanoparticle + Status: Active + Phase: Marketed. The research produces 61 results on March 11, 2019 comprising Liposomes (24), Micelles (9), Injectable emulsion (8), gold/inorganic (4), Polymer (4), homogenization/sonication (3), cationic lipids (3), solid lipid (3), milling (2) and miscellaneous (3: NP hydrogel, nanocrystal and dendrimer)

#### Criteria and resources to determine number of clinical trials ongoing and at present time.

PharmaCircle research in Drug Delivery Technology Analyzer. Keywords used: DD technology: Nanoparticle + Status: Active + Phase: Phase I or Phase 2 or Phase 3. Results obtained 210 on March 11, 2019

#### Criteria and resources to determine number of peer reviewed publications in nanomedicine related areas.

Web of Science Boolean search: (TS=(nanotechnology OR nanoparticle OR nanomaterial) AND TS=(nanomedicine OR drug delivery OR medical device OR therapy OR diagnostic)) AND DOCUMENT TYPES: (Article)  
Indexes=SCI-EXPANDED, CPCI-S, ESCI Timespan=2009-2019  
Results: 22,429 (English language)  
Results: 22,582 (All languages)  
TS=topic